From Our Partners
Thursday, July 7, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

BioFire Receives FDA Clearance for the FilmArray 2.0

by Global Biodefense Staff
February 26, 2015
BioWatch Trigger Detector

BioFire Diagnostics, LLC today announced that it has received FDA clearance and CE-IVD marking of the FilmArray 2.0 system. The system is expected to be commercially available by the end of March 2015.

Since its acquisition by bioMérieux, BioFire Diagnostics has reported more than 60% organic growth in sales at the end of 2014.

FilmArray 2.0 features higher throughput, allowing customers random access processing up to 175 samples in a day within a small footprint. The system offers the same strengths of rapidity, ease-of-use, integration and accuracy that characterize the current FilmArray. Each system accommodates 1 to 8 FilmArray 2.0 units operated by a single computer. The system is also capable of connecting to Laboratory Information Systems.

“As we develop additional applications for the FilmArray system, it is essential that customers are able to accommodate high throughput with as small of a footprint as possible,” said Randy Rasmussen, bioMérieux Corporate Vice President of Molecular Biology and CEO of BioFire Diagnostics. “We look forward to introducing the FilmArray 2.0 system to clinical laboratories throughout the world and are excited for the expected benefits FilmArray’s syndromic approach will have on the fight against infectious diseases, antibiotic stewardship and more broadly on patient care and healthcare cost reduction.”

Currently, the FilmArray menu includes three FDA-cleared and CE-marked panels: the Respiratory Panel, the Blood Culture Identification Panel and the Gastrointestinal Panel.

Additionally, BioFire has initiated studies for its Meningitis-Encephalitis Panel, with FDA submission expected this year.

From Our Partners
Tags: BioterrorismBioWatch

Related Posts

Influenza Research
Biodetection

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
NIH to Further Invest in Point-of-Care Technologies Research Network
Biodetection

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022
Load More

Latest News

Biodefense Headlines – 5 July 2022

Biodefense Headlines – 5 July 2022

July 5, 2022
Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC